Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration”
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Zhongqing Will He, John D. Davis, Lutz O. Harnisch · 2026
Read Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration” by Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Zhongqing Will He, John D. Davis, Lutz O. Harnisch (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13670997.txt.
Description
Nine researchers, led by Sébastien Bihorel, reply in 2026 to comments on their study of aflibercept, a drug injected into the eye for retinal diseases. The exchange concerns how long the drug stays active in the eye and how that shapes the gap between doses.
The authors note that their model tracked how the drug clears from the eye. It predicted that the higher 8 mg dose holds its level about six weeks longer than the 2 mg dose. They describe follow-up analyses linking faster clearance and greater retinal thickness to shorter dosing gaps in trial patients. They welcome wider modeling that ties drug levels to treatment results.
Catalog record
| CREATOR | Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Zhongqing Will He, John D. Davis, Lutz O. Harnisch |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |